• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by PepGen Inc.

    3/4/26 4:20:26 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PEPG alert in real time by email
    S-8 1 pepg-20260304.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 4, 2026

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    PEPGEN INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    85-3819886

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    321 Harrison Avenue

    Boston, Massachusetts 02118

    (781) 797-0979

    (Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

    PepGen Inc. 2022 Stock Option and Incentive Plan

    PepGen Inc. 2022 Employee Stock Purchase Plan

    (Full title of the plan)

     

    James McArthur, Ph.D.

    President and Chief Executive Officer

    PepGen Inc.

    321 Harrison Avenue

    Boston, Massachusetts 02118

    (781) 797-0979

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Edwin O’Connor, Esq.

    Finnbarr Murphy, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

     

    REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTIONS E

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by PepGen Inc. (the “registrant”) with the Securities and Exchange Commission (the “Commission”) to register 3,443,747 additional shares of its common stock, par value $0.0001 per share (the “Common Stock”), reserved for issuance under the PepGen Inc. 2022 Stock Option and Incentive Plan (the “2022 Plan”) and 678,000 additional shares of its Common Stock, reserved for issuance under the 2022 Employee Stock Purchase Plan (the “2022 ESPP”), pursuant to the “evergreen” provisions of the 2022 Plan and the 2022 ESPP.

    The number of shares of Common Stock reserved and available for issuance under the 2022 Plan is subject to an automatic annual increase on each January 1, in an amount equal to the lesser of: (i) 5% of the outstanding shares on the immediately preceding December 31, or (ii) such lesser amount as determined by the Administrator.

    The number of shares of Common Stock reserved and available for issuance under the 2022 ESPP is subject to an automatic annual increase by the lesser of (i) one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, (ii) 678,000 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator.

    The additional shares are of the same class as other securities relating to the 2022 Plan and the 2022 ESPP for which the registrant’s registration statements filed on Form S-8 with the Commission on May 10, 2022 (File No. 333-264822), March 23, 2023 (File No. 333-270790), March 6, 2024 (File No. 333-277708) and February 24, 2025 (File No. 333-285166) are effective.

    Pursuant to General Instruction E of Form S-8 regarding Registration of Additional Securities, the contents of the Registration Statements on Form S-8 filed with the Commission on May 10, 2022 (File No. 333-264822), March 23, 2023 (File No. 333-270790), March 6, 2024 (File No. 333-277708) and February 24, 2025 (File No. 333-285166) are hereby incorporated by reference in this Registration Statement, except to the extent supplemented, amended or superseded by the information set forth herein.

    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    Item 2. Registrant Information and Employee Plan Annual Information.

    The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     


     

    Part II

    Item 8. Exhibits.

    EXHIBIT INDEX

    Exhibit
    No.

    Description

    4.1

    Third Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on June 16, 2022 (File No. 001-41374)).

    4.2

    Certificate of Correction to Third Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q filed on November 10, 2022 (File No. 001-41374)).

    4.3

    Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of PepGen Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 20, 2024 (File No. 001-41374)).

    4.4

    Second Amended and Restated By-laws of the Company (Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on March 15, 2024 (File No. 001-41374)).

    4.5

    Amended and Restated Investors’ Rights Agreement among the Company and certain of its stockholders, dated July 30, 2021 (Incorporated by reference to Exhibit 4.1 to the Registrant’s Company's Statement on Form S-1, as amended (File No. 333-264335)).

    5.1

    *

    Opinion of Goodwin Procter LLP.

    23.1

    *

    Consent of KPMG LLP, Independent Registered Public Accounting Firm.

    23.2

    *

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

    24.1

    *

    Power of Attorney (included on signature page).

    99.1

    2022 Stock Option and Incentive Plan and form of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).

    99.2

    2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).

     

    99.3

     

     

    Form of Non-Qualified Stock Option Agreement for Non-Employee Directors (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 7, 2025 (File No. 001-41374).

    107

    *

    Filing Fee Table

     

    *

     

     

    Filed herewith.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, State of Massachusetts, on this 4th day of March, 2026.

    PEPGEN INC.

    By:

    /s/ James McArthur

    James McArthur, Ph.D.

    President and Chief Executive Officer

     


     

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James McArthur, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated as of March 4, 2026:

    Name

    Title

    /s/ James McArthur

    Chief Executive Officer

    (Principal Executive Officer)

    James McArthur, Ph. D.

     

     

    /s/ Noel Donnelly

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

    Noel Donnelly, M.B.A.

     

     

    /s/ Laurie B. Keating

    Chair of the Board of Directors

    Laurie B. Keating, J.D.

     

     

    /s/ Habib Joseph Dable

    Director

    Habib Joseph Dable

     

     

    /s/ Heidi Henson

    Director

    Heidi Henson

     

     

    /s/ Howard Mayer

     

    Director

    Howard Mayer, M.D.

     

     

     

     

     

    /s/ Joshua Resnick.

    Director

    Joshua Resnick, M.D., M.B.A

     

     

    /s/ Mitchell H. Finer

     

    Director

    Mitchell H. Finer, Ph.D.

     

     

     

     

     

    /s/ Lisa Wyman

     

    Director

    Lisa Wyman, M.S.

     

     

     

     

     

     

     


    Get the next $PEPG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEPG

    DatePrice TargetRatingAnalyst
    9/9/2025$6.00Buy
    Guggenheim
    12/16/2024$3.00Neutral → Underperform
    BofA Securities
    7/31/2024$12.00Buy → Neutral
    BofA Securities
    12/21/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $PEPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PepGen Announces Regulatory Updates on FREEDOM2

    - U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing of the 10 mg/kg cohort continues in the UK and Canada - - PepGen reiterates guidance for reporting data from the FREEDOM2 5 mg/kg cohort in Q1 2026 and from the 10 mg/kg cohort in 2H 2026 - PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, today announced regulatory updates related to the FREEDOM2 trial. The U.S. Food and Drug Administrati

    3/4/26 4:03:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Participate in the Leerink Global Healthcare Conference

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentatio

    3/3/26 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Chief Business and Legal Officer, Joseph Vittiglio. On December 8, 2025, Mr. Vittiglio received a non-qualified stock option grant to purchase 160,000 shares of PepGen's common stock, par value $0.0001 per share, with an exercise price of $5.59 per share, the closing price of PepGen's common stock as reported by The Nasdaq Global S

    12/9/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Former 10% Owner Oxford Science Enterprises Plc bought $640,000 worth of shares (200,000 units at $3.20), increasing direct ownership by 4% to 4,955,388 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    10/1/25 1:07:57 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $30,000,000 worth of shares (9,375,000 units at $3.20) (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    9/30/25 4:35:57 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Head of R&D Streck Paul bought $10,393 worth of shares (8,375 units at $1.24), increasing direct ownership by 43% to 27,805 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    6/2/25 5:03:19 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business & Legal Officer Vittiglio Joseph was granted 30,717 shares, increasing direct ownership by 88% to 65,717 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    3/2/26 5:09:21 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Officer Kasraian Kasra was granted 34,557 shares, increasing direct ownership by 206% to 51,307 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    3/2/26 5:07:18 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Head of R&D Streck Paul was granted 50,300 shares, increasing direct ownership by 181% to 78,105 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    3/2/26 5:05:35 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on PepGen with a new price target

    Guggenheim initiated coverage of PepGen with a rating of Buy and set a new price target of $6.00

    9/9/25 7:59:59 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00

    12/16/24 12:07:01 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00

    7/31/24 11:28:59 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    SEC Filings

    View All

    PepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PepGen Inc. (0001835597) (Filer)

    3/4/26 5:02:16 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by PepGen Inc.

    S-8 - PepGen Inc. (0001835597) (Filer)

    3/4/26 4:20:26 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by PepGen Inc.

    10-K - PepGen Inc. (0001835597) (Filer)

    3/4/26 4:15:51 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Financials

    Live finance-specific insights

    View All

    PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

    – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

    2/24/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

    – PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

    7/30/24 4:02:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

    BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

    3/16/23 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Leadership Updates

    Live Leadership Updates

    View All

    PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance within public biotechnology companies. "Joe is a deeply experienced legal and business leader with a proven track record guiding companies through complex transactions, regulatory milestones, financings, product launches, and stra

    12/8/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

    5/20/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Appointment of Two New Directors to its Board

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies

    3/31/25 4:05:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/14/24 4:31:29 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by PepGen Inc.

    SC 13G - PepGen Inc. (0001835597) (Subject)

    11/14/24 11:10:10 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/12/24 8:57:04 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care